Obstructive sleep apnea, or OSA, affects millions of adults and often goes untreated because the most common therapy – the CPAP machine – can be uncomfortable or difficult to use every night. Many people simply cannot tolerate the mask, the noise, or the feeling of forced air. For years, researchers have been searching for an easier, more comfortable option that still improves breathing during sleep.
A new study published in the American Journal of Respiratory and Critical Care Medicine may represent a major step forward. The Phase 3 SynAIRgy trial evaluated AD109, an investigational once daily pill taken at bedtime. The results suggest that this medication could offer a meaningful alternative for people who cannot or will not use CPAP therapy.
What Is AD109?
AD109 is a combination of two medications: aroxybutynin 2.5 mg and atomoxetine 75 mg. Together, they are designed to target the neuromuscular causes of airway collapse during sleep. Instead of pushing air into the airway like a CPAP machine, AD109 aims to strengthen and stabilize the muscles that keep the airway open.
This approach is different from anything currently approved for OSA. If eventually cleared by the FDA, AD109 could become the first oral medication specifically designed to treat the condition.
Why a Pill Matters for Sleep Apnea
CPAP therapy works extremely well when used consistently, but real‑world adherence is a major challenge. Many people stop using their device or never fully adopt it. The SynAIRgy trial specifically enrolled adults who were either intolerant of CPAP or refused to use it. That means the study focused on the exact group of patients who need alternatives the most.
A once daily pill taken at bedtime is far easier to incorporate into daily life. If effective, it could dramatically expand access to treatment for people who currently have no workable options.
Inside the SynAIRgy Phase 3 Trial
The SynAIRgy trial was a large, randomized, double‑blind, placebo‑controlled study conducted across 69 centers. It included 646 adults with mild, moderate, or severe OSA. Participants were followed for 26 weeks.
Key details from the study population:
- Median age: 58 years
- 49.3 percent female
- Median BMI: 32.4 kg/m2
- Baseline apnea hypopnea index (AHI): 19.6 events per hour
- OSA severity: 35 percent mild, 42 percent moderate, 23 percent severe
The primary goal was to measure how much AD109 reduced the apnea hypopnea index, which is the standard measure of how often breathing stops or becomes shallow during sleep.
What the Study Found
1. Meaningful Reduction in Breathing Disruptions
At week 26, AD109 produced a statistically significant improvement in AHI compared to placebo. The mean treatment difference was -4.0 events per hour, with a model‑estimated 44.1 percent reduction from baseline, compared to 17.6 percent with placebo.
A separate publication from Apnimed reported a 55.6 percent reduction in AHI using a slightly different statistical approach (the treatment estimand), reinforcing the strength of the effect.
2. Improved Oxygenation During Sleep
AD109 also improved oxygenation measures, including:
- Oxygen desaturation index (ODI)
- Hypoxic burden (HB)
One report noted a 60.5 percent reduction in hypoxic burden, which reflects how much total time a person spends with low oxygen levels during sleep.
These improvements matter because low oxygen levels contribute to many of the long‑term health risks associated with sleep apnea, including cardiovascular disease.
3. Mixed Results on Fatigue and Sleep Quality
The study measured patient‑reported fatigue using the PROMIS‑Fatigue scale. Unlike the breathing and oxygenation measures, fatigue did not show a statistically significant improvement compared to placebo.
This does not necessarily mean patients felt no benefit, but it suggests that improvements in breathing do not always translate directly into noticeable changes in daytime symptoms within the study period.
4. Side Effects and Safety
The most common side effects reported with AD109 were:
- Dry mouth
- Nausea
- Insomnia
- Urinary hesitation
About 21.2 percent of participants on AD109 discontinued treatment due to side effects, compared to 3.1 percent on placebo. Importantly, no serious treatment‑related adverse events were reported.
This safety profile will be an important consideration as the FDA reviews the medication.
How AD109 Works
AD109 is designed to address the neuromuscular root cause of airway collapse. According to the companion mechanistic review published alongside the Phase 3 results, the medication works by activating upper airway muscles and improving their responsiveness during sleep.
Atomoxetine increases norepinephrine levels, which can stimulate airway muscle tone. Aroxybutynin reduces muscle overactivity in a way that helps stabilize the airway. Together, they aim to keep the airway open without mechanical pressure.
This biological rationale directly informed the design of the SynAIRgy trial and helps explain why the medication improved objective breathing measures.
What This Could Mean for Patients
If approved, AD109 could become the first oral medication for obstructive sleep apnea. That alone would be a major milestone. But the implications go further.
1. A New Option for CPAP‑Intolerant Patients
Millions of people diagnosed with OSA either stop using CPAP or never start. AD109 could offer a treatment path for these individuals, reducing their risk of long‑term complications.
2. Potential for Broader Access
A pill is easier to distribute, easier to prescribe, and easier to use. It could help reach patients who live far from sleep centers or who cannot afford or manage CPAP equipment.
3. Better Understanding of OSA as a Neuromuscular Condition
The success of AD109 supports the idea that OSA is not just a structural problem but also a neuromuscular one. This could open the door to more targeted therapies in the future.
4. Not a Replacement for CPAP, but a Complement
Even if approved, AD109 will not replace CPAP for everyone. CPAP remains the most effective therapy for reducing AHI to near zero. But for people who cannot tolerate it, AD109 could be life‑changing.
What Comes Next
Apnimed has submitted a New Drug Application (NDA) to the FDA. The agency will review the Phase 3 data, safety profile, and manufacturing information before deciding whether to approve the medication.
If approved, AD109 could become available as a prescription pill taken once nightly at bedtime.
The SynAIRgy Phase 3 trial represents one of the most promising developments in sleep apnea treatment in years. While CPAP will remain the gold standard for many, the possibility of treating OSA with a simple pill could dramatically expand access to care. The improvements in breathing and oxygenation seen in the study are meaningful, and the safety profile appears manageable.
As with any new therapy, long‑term data and real‑world experience will be important. But for now, AD109 offers hope to millions who have struggled with existing treatments.
Better Treatment, Lower Cost – No Catch.
Find safer, more effective medications with fewer side effects – often for less money. It’s fast, free, and personalized. Learn More →
Sources (2)
- American Journal of Respiratory and Critical Care Medicine – Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy)
https://doi.org/10.1093/ajrccm/aamag215 - Apnimed – Company Announcement on SynAIRgy Trial Results
https://apnimed.com/article/apnimed-dual-publication-press-release/